Lupin Launches Generic Cholesterol-Lowering Drug In The U.S.
An employee collects packs of tablets as they move along the production line inside the packaging unit at the Lupin Ltd. pharmaceutical plant in Salcette, Goa. (Photographer: Dhiraj Singh/Bloomberg)

Lupin Launches Generic Cholesterol-Lowering Drug In The U.S.


Drug firm Lupin Ltd. on Monday said it has launched generic cholesterol-lowering Atorvastatin Calcium tablets in the U.S. market.

The company has launched Atorvastatin Calcium tablets USP in the strengths of 10 mg, 20 mg, 40 mg, and 80 mg, having received an approval earlier from the United States Food and Drug Administration, Lupin said in a statement.

The product will be manufactured at the company's Nagpur facility, it added.

The tablets are generic versions of Pfizer Inc.'s Lipitor tablets in the same strengths, Lupin said.

Atorvastatin is indicated to lower cholesterol in blood for adults and children over 10 years of age. It is also prescribed to lower the risk of heart attack and stroke in patients with cardiovascular diseases, diabetes and other risk factors such as eye problems, kidney diseases or high blood pressure, it added.

According to IQVIA moving annual total July 2020 data, Atorvastatin Calcium tablets USP had annual sales of approximately $559 million in the U.S., Lupin said.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.